Matricelf’s autologous regenerative platform is designed to unlock healing in a range of serious medical conditions by enabling the regeneration and replacement of damaged functional tissue.
Our initial and primary focus is on treating spinal cord injury (SCI), where there is a clear regulatory path and an urgent unmet need. While SCI is our current priority, the underlying platform may support future expansion into additional indications, including myocardial infraction, traumatic brain injury and Parkinson’s disease, where personalized tissues regeneration could potentially restore damaged tissues and improve function.
